NCT03627494View on ClinicalTrials.gov

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 30, 2018

Primary Completion Date

August 26, 2019

Study Completion Date

August 26, 2019

Conditions
Muscular Dystrophies
Interventions
DRUG

GSK3439171A

Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

DRUG

Placebo

Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03627494 - First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect | Biotech Hunter | Biotech Hunter